Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Jori B et al. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Current Oncol 2022; Sep 16;29(9):6628-6634. doi: 10.3390/curroncol29090520

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Roeper J et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 2022. Jan;11(1):4-13. doi: 10.21037/tlcr-21-754

TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib

Roeper J et al. TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib. Transl Lung Cancer Res 2021; Jan;11(1):4-13. doi: 10.21037/tlcr-21-754

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

Berger LA et al. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. J Thorac Oncol 2018; Dec;13(12):e243-e246. DOI: 10.1016/j.jtho.2018.08.2025 I2

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

Keppens C et al. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn 2018; Jul;20(4):483-494. DOI: 10.1016/j.jmoldx.2018.03.006

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Scheel AH et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018; Feb;72(3):449-459. doi: 10.1111/his.13375

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

Michels S et al. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. J Thorac Oncol 2016; Jan;11(1):122-7. doi: 10.1016/j.jtho.2015.09.016

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

Scheel AH et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016; Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117

Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing

Christopoulos P et al. Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 2020; Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer

Schatz S et al. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. Cancers 2020; Jun 24;12(6):1685. doi: 10.3390/cancers12061685

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

Roeper J et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget 2020; Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Michels S et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol 2019; Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020.

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)

Frank R et al. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Canc Res 2018; Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Scheel AH et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018; Feb;72(3):449-459. doi: 10.1111/his.13375